GSK (NYSE:GSK) announced Tuesday that the EU drug regulator has agreed to review depemokimab, an experimental monoclonal antibody targeting a class of cell signaling molecules called interleukin-5, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback